Havana, Sep 30.- Cuba continues its progress in the vaccine candidates against Covid-19, as revealed in a meeting held between Eduardo Martínez Díaz, president of BioCubaFarma , and scientific institutions involved in the process.
This was reported by the Cuban biotechnology business group through its Twitter account: “This morning the President of # BioCubaFarma checked with managers and researchers from @ FinlayInstituto , @ centro_cim and @ CIGBCuba the progress of the vaccine projects against the # Covid19 of the sector. It continues to advance. # CienciaCubana # VacunasCubanasCovid19 ”.
Soberana01 is the first Cuban vaccine candidate that is in the phase of clinical trials in humans, an evaluation that is carried out in a random and controlled manner, and is expected to conclude, in all its stages, in January of next year.
At the beginning of September, around 20 Cubans between 60 and 80 years of age joined the study as the second group of volunteers to receive the first dose of the drug and demonstrate its safety.
The injectable product, developed by the Finlay Vaccine Institute , is based on the principle of the Cuban vaccine against meningococcal meningitis , with almost 30 years of efficacy, and is combined with the RBD antigen, which facilitates the entry of the pathogen into cells of the human body.
Soberana 01 is also the first vaccine candidate in Latin America and the Caribbean to receive authorization for clinical trials and the number 30 in the world. (ACN) (Photo: File)